Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.xcrm.2020.100059 http://scihub22266oqcxt.onion/10.1016/j.xcrm.2020.100059 32835306!7373044!32835306     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Cell+Rep+Med 2020 ; 1 (4): 100059 Nephropedia Template TP {{tp|p=32835306|t=2020. Characterization and Treatment of SARS-CoV-2 in Nasal and Bronchial Human Airway Epithelia |pdf=|usr=}}{{32835306}} gab.com Text Characterization and Treatment of SARS-CoV-2 in Nasal and Bronchial Human Airway Epithelia JO: Cell Rep Med http://www.kidney.de/pget.php?&tw=1&pmid=32835306 #FOAvip In the current COVID-19 pandemic context, proposing and validating effective treatments represents a major challenge. However, the scarcity of biologically relevant pre-clinical models of SARS-CoV-2 infection imposes a significant barrier for scientific and medical progress, including the rapid transition of potentially effective treatments to the clinical setting. We use reconstituted human airway epithelia to isolate and then characterize the viral infection kinetics, tissue-level remodeling of the cellular ultrastructure, and transcriptional early immune signatures induced by SARS-CoV-2 in a physiologically relevant model. Our results emphasize distinctive transcriptional immune signatures between nasal and bronchial HAE, both in terms of kinetics and intensity, hence suggesting putative intrinsic differences in the early response to SARS-CoV-2 infection. Most important, we provide evidence in human-derived tissues on the antiviral efficacy of remdesivir monotherapy and explore the potential of the remdesivir-diltiazem combination as an option worthy of further investigation to respond to the still-unmet COVID-19 medical need. Twit Text FOAVip Characterization and Treatment of SARS-CoV-2 in Nasal and Bronchial Human Airway Epithelia ????Cell Rep Med http://www.kidney.de/pget.php?&tw=1&pmid=32835306 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32835306 #FOAvip English Wikipedia <ref>{{Cite pmid|32835306}}</ref> Characterization and Treatment of SARS-CoV-2 in Nasal and Bronchial Human Airway Epithelia #MMPMID32835306 Pizzorno A; Padey B; Julien T; Trouillet-Assant S; Traversier A; Errazuriz-Cerda E; Fouret J; Dubois J; Gaymard A; Lescure FX; Duliere V; Brun P; Constant S; Poissy J; Lina B; Yazdanpanah Y; Terrier O; Rosa-Calatrava M Cell Rep Med 2020[Jul]; 1 (4): 100059 PMID32835306show ga In the current COVID-19 pandemic context, proposing and validating effective treatments represents a major challenge. However, the scarcity of biologically relevant pre-clinical models of SARS-CoV-2 infection imposes a significant barrier for scientific and medical progress, including the rapid transition of potentially effective treatments to the clinical setting. We use reconstituted human airway epithelia to isolate and then characterize the viral infection kinetics, tissue-level remodeling of the cellular ultrastructure, and transcriptional early immune signatures induced by SARS-CoV-2 in a physiologically relevant model. Our results emphasize distinctive transcriptional immune signatures between nasal and bronchial HAE, both in terms of kinetics and intensity, hence suggesting putative intrinsic differences in the early response to SARS-CoV-2 infection. Most important, we provide evidence in human-derived tissues on the antiviral efficacy of remdesivir monotherapy and explore the potential of the remdesivir-diltiazem combination as an option worthy of further investigation to respond to the still-unmet COVID-19 medical need. |Adenosine Monophosphate/analogs & derivatives/pharmacology[MESH] |Airway Remodeling[MESH] |Alanine/analogs & derivatives/pharmacology[MESH] |Animals[MESH] |Antiviral Agents/*pharmacology[MESH] |Bronchi/drug effects/immunology/ultrastructure/*virology[MESH] |COVID-19 Drug Treatment[MESH] |COVID-19/immunology/pathology/virology[MESH] |Chlorocebus aethiops[MESH] |Diltiazem/pharmacology[MESH] |Drug Synergism[MESH] |Humans[MESH] |Immunity, Innate[MESH] |Models, Biological[MESH] |Nose/drug effects/immunology/ultrastructure/*virology[MESH] |Respiratory Mucosa/drug effects/immunology/ultrastructure/*virology[MESH] |SARS-CoV-2/*drug effects/growth & development[MESH]Characterization and Treatment of SARS-CoV-2 in Nasal and Bronchial Hu(epmc).pdf DeepDyve Pubget Overpricing